ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0521

Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression

Yukitomo Hagiwara1, Goh Murayama2, Taiga Kuga3, Yujin Nishioka4, Masaki Nojima1, Takumi Saito5, Yu Yamaji6, Tomoko Miyashita6, Makio Kusaoi7, Ken Yamaji5 and Naoto Tamura8, 1Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, 3Juntendo University, Tokyo, Japan, 4Juntendo University, Department of Internal Medicine and Rheumatology, Shizuoka, Japan, 5Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, 6Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, 7Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo, Tokyo, Japan, 8Juntendo University School of Medicine, Tokyo, Japan

Meeting: ACR Convergence 2025

Keywords: B-Lymphocyte, Mesenchymal stem cells, Monocytes/macrophages, Sjögren's syndrome, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Primary Sjögren’s disease (pSD) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth and dry eyes. In this study, we investigated the anti-inflammatory effects of umbilical cord-derived mesenchymal stem cells (MSCs) on salivary gland pathology and the involvement of Bach2.

Methods: Peripheral blood mononuclear cells (PBMCs) from pSD patients were co-cultured with MSCs under various stimulatory conditions to evaluate the inhibition of cell differentiation and cytokine production. CD4+ T cells and B cells were isolated from the peripheral blood of pSD patients and co-cultured with MSCs stimulated with pSD-associated autoantigens. The changes in cell subsets and the suppression of IgG production due to MSC inhibitory effects were evaluated. Cell damage was induced in human salivary gland cell lines (HSGs) using H2O2, and the frequency of dead cells was compared. The above experiment was performed under conditions with and without contact cell-to-cell. Bach2 expression in T cells, B cells, and monocytes was also evaluated by Western blotting.

Results: MSCs decreased the production of IFN-γ and IL-4 on T cells and TNF-α on monocytes without cell-to-cell contact with MSCs. Co-culturing B cells from pSD patients with MSCs in the presence of CpG-ODN significantly reduced the proportion of plasma cells and increased the proportion of memory B cells compared to B cell monocultures. Similar results were obtained under non-contact cell-to-cell conditions. Furthermore, when CD4⁺T cells and B cells were co-cultured in the presence of pSD-associated autoantigen, IgG production was suppressed under cell-to-cell contact with MSCs compared to without MSCs. In the induction of cell damage against HSGs, the frequency of dead cells was significantly reduced under non-contact with MSCs. In addition, Bach2 expression in T cells, B cells, and monocytes was enhanced when co-cultured with MSCs in the presence of various stimulations.

Conclusion: In this study, we found that the critical function of MSCs is to induce Bach2 expression in target cells through cell-independent, soluble factors. MSCs control cytokine production and excessive autoantibody production in target cells by inducing Bach2 expression, and even prevent cell death in salivary gland cells. Conventional pSD therapy has not achieved sufficient improvement in salivary gland secretion flow through the use of immunosuppressive drugs. MSCs hold potential as an innovative pSD therapy, including for salivary gland disorders.


Disclosures: Y. Hagiwara: Cell Exosome Therapeutics Co., Ltd., 5; G. Murayama: Cell Exosome Therapeutics Co., Ltd., 5; T. Kuga: None; Y. Nishioka: None; M. Nojima: None; T. Saito: None; Y. Yamaji: None; T. Miyashita: None; M. Kusaoi: Cell Exosome Therapeutics Co., Ltd., 5; K. Yamaji: None; N. Tamura: AbbVie/Abbott, 6, Asahi Kasei, 5, 6, AstraZeneca, 6, Ayumi, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, 6, Cell Exosome Therapeutics Co., Ltd., 5, Chugai, 5, 6, Daiichi Sankyo, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Kissei, 6, Novartis, 6, Taisho, 5, UCB, 6.

To cite this abstract in AMA style:

Hagiwara Y, Murayama G, Kuga T, Nishioka Y, Nojima M, Saito T, Yamaji Y, Miyashita T, Kusaoi M, Yamaji K, Tamura N. Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/umbilical-cord-derived-mesenchymal-stem-cells-suppress-the-pathogenesis-of-primary-sjogrens-disease-by-inducing-bach2-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/umbilical-cord-derived-mesenchymal-stem-cells-suppress-the-pathogenesis-of-primary-sjogrens-disease-by-inducing-bach2-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology